Takada T, Yasuda H, Uchiyama K, Hasegawa H
Gan To Kagaku Ryoho. 1985 May;12(5):1088-93.
In order to study the antitumor effect of FT-207 in a solid tumor, it is necessary to determine the concentration of 5-FU and FT-207 in a tissue. This has only been done so far for gastric cancer and colon cancer, but these has been practically no research carried out regarding cancers of the liver, biliary tract and pancreas. A study was therefore made of lymph nodes and tissues after rectal administration of FT-207 suppositories to 12 patients with cancers of the liver, biliary tract and pancreas. These included 7 cases of pancreatic cancer, 2 cases of gall bladder cancer with infiltration to the liver, and 3 cases of hepatoma. In serum, the concentration of 5-FU reached 0.018 +/- 0.006 micrograms/ml at one hour after administration, 0.019 +/- 0.004 micrograms/ml at three hours after administration, and 0.023 +/- 0.008 micrograms/ml at six hours after administration. These concentrations would be expected to maintain a clinically sufficient dose. The concentration of 5-FU in metastatic lymph nodes was high compared with normal lymph nodes (p less than 0.05), its concentration in liver tumors was high while compared with normal liver tissues (p less than 0.05).
为了研究FT - 207在实体瘤中的抗肿瘤作用,有必要测定组织中5 - FU和FT - 207的浓度。到目前为止,仅对胃癌和结肠癌进行了此项测定,但对于肝癌、胆管癌和胰腺癌几乎没有相关研究。因此,对12例肝癌、胆管癌和胰腺癌患者直肠给予FT - 207栓剂后的淋巴结和组织进行了研究。其中包括7例胰腺癌、2例浸润至肝脏的胆囊癌和3例肝癌。血清中,给药后1小时5 - FU浓度达到0.018±0.006微克/毫升,给药后3小时为0.019±0.004微克/毫升,给药后6小时为0.023±0.008微克/毫升。这些浓度有望维持临床有效剂量。与正常淋巴结相比,转移淋巴结中5 - FU浓度较高(p<0.05),与正常肝组织相比,肝肿瘤中其浓度较高(p<0.05)。